Company profile for Verona Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our proprietary lead candidate, RPL554, is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory con...
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Our proprietary lead candidate, RPL554, is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
3 More London Riverside, London SE1 2RE
Telephone
Telephone
+44 (0)203 283 4200
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

BePharma

Not Confirmed

envelop Contact Supplier

BePharma

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.merck.com/news/merck-completes-acquisition-of-verona-pharma/

PRESS RELEASE
07 Oct 2025

https://www.globenewswire.com/news-release/2025/09/16/3150586/0/en/Verona-Pharma-to-Present-Additional-Analyses-of-the-Phase-3-ENHANCE-Studies-in-COPD-at-ERS-International-Congress-2025.html

GLOBENEWSWIRE
16 Sep 2025

https://www.fiercepharma.com/pharma/its-10b-buyout-verona-merck-was-lone-ranger

FIERCE PHARMA
07 Aug 2025

https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/

PRESS RELEASE
10 Jul 2025

https://www.globenewswire.com/news-release/2025/05/21/3085542/0/en/Verona-Pharma-Announces-June-2025-Investor-Conference-Participation.html

GLOBENEWSWIRE
21 May 2025

https://www.globenewswire.com/news-release/2025/05/06/3074811/0/en/Verona-Pharma-to-Present-Seven-Analyses-of-the-Phase-3-ENHANCE-Studies-in-COPD-at-ATS-2025.html

GLOBENEWSWIRE
06 May 2025

FDA Orange Book

read-more
read-more

01

Brand Name : OHTUVAYRE

BePharma
Not Confirmed
arrow

Brand Name : OHTUVAYRE

BePharma
Not Confirmed
arrow

Verona Pharma

Dosage Form : SUSPENSION; INHALATION

Proprietary Name : OHTUVAYRE

Dosage Strength : 3MG/2.5ML

Approval Date : 2024-06-26

Application Number : 217389

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

Listed Dossiers

read-more
read-more

01

Brand Name : Ohtuvayre

BePharma
Not Confirmed
arrow

Brand Name : Ohtuvayre

arrow
BePharma
Not Confirmed

Verona Pharma

Dosage Form :

Brand Name : Ohtuvayre

Dosage Strength :

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : United Kingdom

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty